North America Synthetic Biology Market

North America Synthetic Biology Market Size (2023 to 2028)

The size of the Synthetic Biology Market in North America was worth USD 2.15 billion in 2023 and is projected to grow at a CAGR of 25.1%, to reach USD 6.59 billion by 2028.

The factors that are boosting the growth of the synthetic biologic market in North America are increasing applications in many areas like in agriculture the farmers can increase productivity and yield of crops with the help of synthetic biologics, the influx of funding by private organizations and research academies for developing novel biologic products, advancements in genetic engineering, rising demand for synthetic cell and genes, presence of major players in the region. Initiatives by the governments to decrease DNA synthesis and sequencing costs are also boosting the growth of the North American synthetic biologics market.

The issues associated with biosecurity are posing a significant challenge for key players and are limiting the growth rate of the North American synthetic biologics market. Complexities in functionalities of biologics due to uncertainties and the non-linear nature of artificial biologic systems are also posing challenges for the growth of the synthetic biologics market in this area. Environmental concerns associated with accidental exposure of pathogens into the atmosphere are likely to restrain the growth of the North American synthetic biologics market during the forecast period. 

Increasing awareness among people about the effective treatment procedures in developing nations is likely to boost the market's demand and increase growth opportunities for the key players in the North American synthetic biologics market during the outlook period. Increasing focus on initiatives from private and public organizations for developing innovative synthetic biologic vaccines and drugs is expected to create growth opportunities for the market in North America. Increasing concerns over fuel consumption and demand for biofuels are foreseen to provide lucrative growth opportunities for the North American synthetic biologics market. The emergence of innovative synthetic biologic products due to intensive research and development activities by various companies offers promising future opportunities for the synthetic biologics market in North America.

This research report on the North American synthetic biology market has been segmented & sub-segmented into the following categories:

By Tool: 

• Chassis Organisms
• Cloning & Assembly Kits
• Oligonucleotide Synthesis
• Enzymes
• Xeno Nucleic Acid

By Technology: 

• Enabling technologies
  • Gene Synthesis
  • Cloning and Sequencing
  • Genome Engineering
  • Bioinformatics
  • Nanotechnology
  • Site-Directed Mutagenesis
  • Microfluidics
  • Measurement and Modelling
• Enabled technologies
  • Next-Generation Sequencing
  • Pathway Engineering

By Application: 

• Medical
• Environmental
• Industrial

By Country:

• The United States
• Canada
• Rest of North America

Based on region, the North American regional market is expected to lead the global synthetic biology market during the forecast period due to the presence of many companies in synthetic biology and increasing investments from the government.

KEY MARKET PLAYERS:

A few of the promising companies operating in the North American synthetic biology market profiled in this report are Dupont, Intrexon Corporation, Amyris, Inc., Genscript USA, Inc., Integrated Dna Technologies (IDT), Inc., Novozymes, Royal DSM N.V, New England Biolabs, Inc., Synthetic Genomics, Inc. and Thermo Fisher Scientific, Inc.